Treatment of stable chronic obstructive pulmonary disease: The GOLD guidelines

American Family Physician

Volumn 88, Issue 10, 2013, Pages 655-663

  Lee, Hobart ^a   Kim, Jeffrey ^a   Tagmazyan, Karine ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ARFORMOTEROL; AZITHROMYCIN; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; COMBIVEN RESPIMAT; ERYTHROMYCIN; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LEVALBUTEROL; LONG ACTING DRUG; MOMETASONE FUROATE; PIRBUTEROL; PIRBUTEROL ACETATE; ROFLUMILAST; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ALLERGIC REACTION; ANAPHYLAXIS; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; ATRIOVENTRICULAR BLOCK; BRAIN PSEUDOTUMOR; BRONCHOSPASM; CARDIOPULMONARY ARREST; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT TOOL; COPD ASSESSMENT TEST; DISEASE EXACERBATION; DYSPNEA; EPILEPTIC STATE; FAINTNESS; FEVER; FORCED EXPIRATORY VOLUME; GLAUCOMA; GOLD GUIDELINE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOTENSION; INFLUENZA VACCINATION; INTRAOCULAR PRESSURE; KIDNEY FAILURE; LARYNX SPASM; LEUKOCYTOSIS; LUNG CANCER; LUNG RESECTION; LUNG TRANSPLANTATION; META ANALYSIS (TOPIC); METABOLIC ACIDOSIS; MUSCLE INJURY; OXYGEN THERAPY; PARESTHESIA; PELVIC INFLAMMATORY DISEASE; PEPTIC ULCER; PNEUMONIA; PRACTICE GUIDELINE; PROSTATE CANCER; PULMONARY REHABILITATION; QT PROLONGATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SIDE EFFECT; SMOKING CESSATION; SPIROMETRY; STRIDOR; SUICIDAL IDEATION; TACHYCARDIA; VASCULITIS; VOMITING; WHEEZING;

EID: 84888122394     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61(46): 938-943.
2. Centers for Disease Control and Prevention. Deaths from chronic obstructive pulmonary disease-United States, 2000-2005. MMWR Morb Mortal Wkly Rep. 2008; 57(45): 1229-1232.
3. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011. http://www. goldcopd. org/guidelines-global-strategy-for-diagnosis-management. html. Accessed September 16, 2013.
4. Gruffydd-Jones K, Loveridge C. The 2010 NICE COPD guidelines: how do they compare with the GOLD guidelines? Prim Care Respir J. 2011; 20(2): 199-204.
5. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011; 155(3): 179-191.
6. Stephens MB, Yew KS. Diagnosis of chronic obstructive pulmonary disease. Am Fam Physician. 2008; 78(1): 87-92.
7. Barreiro TJ, Perillo I. An approach to interpreting spirometry. Am Fam Physician. 2004; 69(5): 1107-1114.
8. Global Strategy for the Diagnosis, Management and Prevention of COPD. http://www. goldcopd. org/other-resources-gold-teaching-slide-set. html. Accessed August 20, 2013.
9. Agusti A, Calverley PM, Celli B, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010; 11: 122.
10. Tsiligianni IG, van der Molen T, Moraitaki D, et al. Assessing health status in COPD. A head-to-head comparison between the COPD Assessment Test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med. 2012; 12: 20.
11. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959; 2(5147): 257-266.
12. Hurst JR, Vestbo J, Anzueto A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12): 1128-1138.
13. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011; 66(7): 585-590.
14. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272 (19): 1497-1505.
15. Larzelere MM, Williams DE. Promoting smoking cessation. Am Fam Physician. 2012; 85(6): 591-598.
16. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006; (1): CD002733.
17. Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010; (11): CD001390.
18. Nici L, Lareau S, ZuWallack R. Pulmonary rehabilitation in the treatment of chronic obstructive pulmonary disease. Am Fam Physician. 2010; 82(6): 655-660.
19. Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002; (4): CD001495.
20. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006; (2): CD001387.
21. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994; 105(5): 1411-1419.
22. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (2): CD002876.
23. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) [published correction appears in Eur Respir J. 1997; 10(7): 1696]. Eur Respir J. 1997; 10(4): 815-821.
24. Calverley PM, Anderson JA, Celli B, et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8): 775-789.
25. Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥ 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011; 33(12): 1974-1984.
26. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics. 2011; 128(5): e1147-e1154.
27. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; (9): CD009157.
28. Aaron SD, Vandemheen KL, Fergusson D, et al.; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146(8): 545-555.
29. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005; 26(2): 214-222.
30. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis [published correction appears in JAMA. 2009; 301(12): 1227-1230]. JAMA. 2008; 300(12): 1439-1450.
31. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(10): 948-955.
32. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010; 137(1): 13-19.
33. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008; 177(1): 19-26.
34. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(8): 741-750.
35. Grimes GC, Manning JL, Patel P, Via RM. Medications for COPD: a review of effectiveness. Am Fam Physician. 2007; 76(8): 1141-1148.
36. Ram FS, Jardin JR, Atallah A, et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005; 99(2): 135-144.
37. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials [published correction appears in Lancet. 2010; 376(9747): 1146]. Lancet. 2009; 374(9691): 685-694.
38. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al.; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691): 695-703.
39. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008; 178(11): 1139-1147.
40. Albert RK, Connett J, Bailey WC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD [published correction appears in N Engl J Med. 2012; 366(14): 1356]. N Engl J Med. 2011; 365(8): 689-698.
41. Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (3): CD005374.
42. Bradley JM, O'Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (4): CD004356.
43. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980; 93(3): 391-398.
44. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [published correction appears in Eur Respir J. 2006; 27(1): 242]. Eur Respir J. 2004; 23(6): 932-946.
45. Sanchez PG, Kucharczuk JC, Su S, Kaiser LR, Cooper JD. National Emphysema Treatment Trial redux: accentuating the positive. J Thorac Cardiovasc Surg. 2010; 140(3): 564-572.
46. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001; 345(15): 1075-1083.
47. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(10): 1005-1012.